Biotech Archives - Page 17 of 795

1 minute read

23andMe Therapeutics Present Preliminary Phase 2 Safety And Efficacy Results For 23ME-00610, Targeting CD200R1, At The 2024 ASCO Annual Meeting

June 3, 8:21 AM

– 23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit, including one confirmed partial response – 23ME-00610 monotherapy continues to demonstrate acceptable safety and tolerability, and

1 minute read

Tonix Pharmaceuticals To Present New Data On Tonmya Suggesting Activity For Improvement In Fibromyalgia-Associated Depression Severity In An Oral Presentation At ASCP Annual Meeting

By Benzinga Newsdesk

June 3, 8:19 AM

Tonmya treatment was associated with improvement in depressive symptoms as measured by the Beck Depression Inventory-II In addition, post-hoc analyses showed improvement in depression, anxiety, memory and energy

TNXP

1 minute read

Mainz Biomed Presents New Study Data For ColoFuture And eAArly DETECT Study Performance With Sensitivity For CRC Of 92% And 82% For Advanced Adenomas, Including 95.8% Detection Of High-Grade Dysplasia

By Benzinga Newsdesk

June 3, 8:16 AM

New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Results from pooled

MYNZ

3 minute read

Summit Therapeutics Ivonescimab In Combination with Chemotherapy Approved In China By NMPA For 2L+ EGFRm NSCLC Based On HARMONi-A Clinical Trial; Clinically Meaningful Efficacy Observed In Overall Survival Towards Ivonescimab Plus Chemotherapy; Shares…

By Benzinga Newsdesk

May 31, 10:04 PM

Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0.46For Subset of Patients Previously Receiving 3rd Generation

SMMT

2 minute read

Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile

By Vandana Singh

May 31, 2:25 PM

Discover the results of Ionis Pharmaceuticals' Phase 3 studies on donidalorsen for hereditary angioedema. FDA application submission expected this year.

IONS

2 minute read

FDA Expands Approval For Bristol Myers Squibb’s Breyanzi, Making CAR T Cell Therapy Available For Broadest Range Of B-Cell Malignancies

By Vandana Singh

May 31, 2:14 PM

FDA approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) for relapsed or refractory mantle cell lymphoma, marking its fourth non-Hodgkin lymphoma subtype indication.

BMY

2 minute read

Novartis Sues to Block Maryland’s New Drug Discount Law

By Vandana Singh

May 31, 2:12 PM

Novartis has filed a lawsuit to block a Maryland law requiring drugmakers to offer discounts on drugs through third-party pharmacies contracting with hospitals and clinics.

NVS

2 minute read

Novo Nordisk Sues Additional US Clinics Against Fake Semaglutide Products Used For Weight Loss, Diabetes

By Vandana Singh

May 31, 2:08 PM

Novo Nordisk has filed lawsuits against nine additional U.S. medical spas, wellness clinics, and pharmacies for selling impure or falsely labeled semaglutide products.

LLY